Consensus $6.78. Raises FY25 revenue view to $3.06B-$3.07B from $3.04B-$3.06B, consensus $3.05B. Backs FY25 capital spending view $275M. The company said, “Adjusted-diluted EPS guidance assumes a $0.27 benefit based on current foreign exchange rates, unchanged from previous guidance.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical reports Q3 adjusted EPS $1.96, consensus $1.69
- Is WST a Buy, Before Earnings?
- West Pharmaceutical added to ‘Tactical Outperform’ list at Evercore ISI
- West Pharmaceutical price target raised to $275 from $260 at Barclays
- Strong Market Position and Growth Potential Justify Buy Rating for West Pharmaceutical Services